Skip to main content
. Author manuscript; available in PMC: 2011 Oct 1.
Published in final edited form as: Clin Cancer Res. 2010 Sep 21;16(19):4702–4710. doi: 10.1158/1078-0432.CCR-10-0939

Figure 2.

Figure 2

Kaplan Meier curves illustrating an overall survival advantage for patients with triple negative metastastic breast cancer treated with the PARP inhibitor, BSI-201 (BiPAR Sciences/Sanofi Aventis) plus carboplatin/gemcitabine chemotherapy compared to chemotherapy alone (12.2 versus 7.2 months, p = 0.005)(36).